Literature DB >> 22544199

Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.

G M Hunt1, J Ledwaba, A E Basson, J Moyes, C Cohen, B Singh, S Bertagnolio, M R Jordan, A Puren, L Morris.   

Abstract

Surveillance of human immunodeficiency virus type 1 transmitted drug resistance (TDR) was conducted among pregnant women in South Africa over a 5-year period after the initiation of a large national antiretroviral treatment program. Analysis of TDR data from 9 surveys conducted between 2005 and 2009 in 2 provinces of South Africa suggests that while TDR remains low (<5%) in Gauteng Province, it may be increasing in KwaZulu-Natal, with the most recent survey showing moderate (5%-15%) levels of resistance to the nonnucleoside reverse transcriptase inhibitor drug class.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544199      PMCID: PMC3572869          DOI: 10.1093/cid/cir1017

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay.

Authors:  John W Hargrove; Jean H Humphrey; Kuda Mutasa; Bharat S Parekh; J Steve McDougal; Robert Ntozini; Henry Chidawanyika; Lawrence H Moulton; Brian Ward; Kusum Nathoo; Peter J Iliff; Ekkehard Kopp
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

2.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.

Authors:  Diane E Bennett; Mark Myatt; Silvia Bertagnolio; Donald Sutherland; Charles F Gilks
Journal:  Antivir Ther       Date:  2008

3.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

Authors:  Diane E Bennett; Silvia Bertagnolio; Donald Sutherland; Charles F Gilks
Journal:  Antivir Ther       Date:  2008

4.  Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay.

Authors:  J Steven McDougal; Bharat S Parekh; Michael L Peterson; Bernard M Branson; Trudy Dobbs; Marta Ackers; Marc Gurwith
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

5.  Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Authors:  Barbara S Taylor; Gillian Hunt; Elaine J Abrams; Ashraf Coovadia; Tammy Meyers; Gayle Sherman; Renate Strehlau; Lynn Morris; Louise Kuhn
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-23       Impact factor: 2.205

6.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence.

Authors:  Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

7.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

8.  Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.

Authors:  Visva Pillay; Johanna Ledwaba; Gillian Hunt; Mpho Rakgotho; Beverly Singh; Lindiwe Makubalo; Diane E Bennett; Adrian Puren; Lynn Morris
Journal:  Antivir Ther       Date:  2008

9.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Authors:  Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

10.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Tommy F Liu; Soo-Yon Rhee; Mark Kiuchi; Stephane Hue; Deenan Pillay; Robert W Shafer
Journal:  Bioinformatics       Date:  2009-03-20       Impact factor: 6.937

View more
  26 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa.

Authors:  Barbara S Mensch; Pamina M Gorbach; Cliff Kelly; Photini Kiepiela; Kailazarid Gomez; Gita Ramjee; Shayhana Ganesh; Neetha Morar; Lydia Soto-Torres; Urvi M Parikh
Journal:  AIDS Behav       Date:  2015-11

3.  Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa.

Authors:  Benjamin Chimukangara; Ayesha B M Kharsany; Richard J Lessells; Kogieleum Naidoo; Soo-Yon Rhee; Justen Manasa; Tiago Gräf; Lara Lewis; Cherie Cawood; David Khanyile; Karidia Diallo; Kassahun A Ayalew; Robert W Shafer; Gillian Hunt; Deenan Pillay; Salim Karim Abdool; Tulio de Oliveira
Journal:  AIDS Res Hum Retroviruses       Date:  2019-01-07       Impact factor: 2.205

4.  Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.

Authors:  Nozomi Kuse; Mohammad Arif Rahman; Hayato Murakoshi; Giang Van Tran; Takayuki Chikata; Madoka Koyanagi; Kinh Van Nguyen; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

5.  New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations.

Authors:  Thibaut Davy-Mendez; Joseph J Eron; Laurence Brunet; Oksana Zakharova; Ann M Dennis; Sonia Napravnik
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

6.  Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

Authors:  Carole L Wallis; Evgenia Aga; Heather Ribaudo; Shanmugam Saravanan; Michael Norton; Wendy Stevens; Nagalingeswaran Kumarasamy; John Bartlett; David Katzenstein
Journal:  Clin Infect Dis       Date:  2014-05-01       Impact factor: 9.079

Review 7.  Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.

Authors:  Richard J Lessells; Ava Avalos; Tulio de Oliveira
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

8.  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Yuan-Fang Wang; Arun K Ghosh; Kalapala Venkateswara Rao; Chun-Xiao Xu; Jane M Sayer; John M Louis; Irene T Weber
Journal:  J Med Chem       Date:  2013-05-01       Impact factor: 7.446

9.  Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens.

Authors:  Urvi M Parikh; John W Mellors
Journal:  Future Microbiol       Date:  2012-08       Impact factor: 3.165

10.  Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.

Authors:  Louise Kuhn; Gillian Hunt; Karl-Günter Technau; Ashraf Coovadia; Johanna Ledwaba; Sam Pickerill; Martina Penazzato; Silvia Bertagnolio; Claude A Mellins; Vivian Black; Lynn Morris; Elaine J Abrams
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.